Supriya Lifescience Limited has released the transcript of its Q1 FY27 earnings call, held on August 14, 2026. The discussion covers the company’s financial performance, including ₹190 crore in revenue and an EBITDA of ₹47 crore for the quarter. Management also addressed strategic initiatives, new product launches, geographical performance, and future growth prospects, aiming for ₹1,000 crore in revenue by FY27.
Supriya Lifescience Releases Q1 FY27 Earnings Call Transcript
Supriya Lifescience Limited has officially published the transcript from its Q1 FY27 Earnings Conference Call, which took place on August 14, 2026. The document provides a detailed overview of the company’s performance during the quarter ended June 30, 2026, and insights into its strategic direction.
Financial Highlights for Q1 FY27
During the call, management reported that revenue for the quarter stood at ₹190 crore, marking a 31% year-on-year growth. Despite strong demand, water shortages led to an estimated deferment of sales totaling ₹35 crore. EBITDA for the quarter was reported at ₹47 crore, a 8.1% decline year-on-year, with EBITDA margins at 25%. This margin dip was attributed to temporary factors such as increased fuel and power costs due to a change in Maharashtra’s solar power policy (impacting EBITDA by ₹8 crore) and water scarcity in the Lote MIDC area.
Key Business Updates and Strategic Outlook
Exports continue to be a significant growth driver, accounting for 81% of revenue in Q1 FY27, with Asia, Europe, and LATAM contributing 39%, 35%, and 20% respectively. The company is progressing with its backward integration strategy, with 72% of total revenues now fully integrated. New product launches are on track, with two anesthetic liquid inhalation products introduced in Q2 FY27 and two ADHD product launches planned. Supriya Lifescience remains confident in its trajectory towards achieving ₹1,000 crore in revenue by FY27, supported by a robust product pipeline and sustained demand across key therapeutic segments.
Operational and Future Plans
The company is investing in capacity building, including the Patalganga facility, which will involve an estimated ₹200 crore for Phase-1. Discussions are ongoing for CMO-CDMO collaborations, with a significant anesthetic CDMO contract nearing finalization. Supriya Lifescience is also expanding its R&D capabilities with new facilities at Ambernath. The company anticipates that its EBITDA margins will stabilize in the range of 33% to 35% over the next three to four years, driven by a focus on adding new verticals and products.
Source: BSE
